Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Insomnia and Cognition in Elderly Patients With Mental Disorders (Real-World Study)
ChiCTR2600119248Phase 4Recruiting
- Sponsor
- Peking University Huilongguan Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lemborexant in Insomnia, major depressive disorder (MDD), Alzheimer's disease (AD) and 2 more, sponsored by Peking University Huilongguan Hospital. Primary endpoint: Insomnia Severity Index (ISI) at week 24. Started Feb 2026; status: recruiting.
02
Drugs
lemborexant
03
Conditions
Insomniamajor depressive disorder (MDD)Alzheimer's disease (AD)schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on ChiCTR2600119248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119248.